The Development of Vancomycin Resistance in a Patient with Methicillin-ResistantStaphylococcus aureusInfection
| Autor: | Alexander Tomasz, Stuart W. Haber, Krzysztof Sieradzki, Richard B. Roberts |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Staphylococcus aureus Micrococcaceae Lactams medicine.drug_class Antibiotics Microbial Sensitivity Tests Drug resistance medicine.disease_cause Microbiology Fatal Outcome Pharmacotherapy Vancomycin medicine Humans Chromatography High Pressure Liquid Aged Antibacterial agent biology business.industry Drug Resistance Microbial General Medicine Staphylococcal Infections biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Methicillin-resistant Staphylococcus aureus Anti-Bacterial Agents Electrophoresis Gel Pulsed-Field Kidney Failure Chronic Drug Therapy Combination Methicillin Resistance New York City business medicine.drug |
| Zdroj: | New England Journal of Medicine. 340:517-523 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm199902183400704 |
| Popis: | Over the past two decades, vancomycin has been considered the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Indeed, multidrug-resistant clones of MRSA for which the only available effective antibacterial agent is vancomycin have recently been identified. Recent reports describing the therapeutic failure of vancomycin for MRSA infections have aroused considerable concern regarding the emergence of MRSA strains for which there will be no effective therapy.1–3 The mechanism of reduced susceptibility in these staphylococcal strains has not been identified, although data indicate that it is not the same as the vancomycin-resistance mechanism in enterococcal strains.4 We describe here . . . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|